MBX Biosciences, Inc. (NasdaqGS: MBX)
Health Care · Pharmaceuticals · US
$53.24
-9.01% today · +267.2% 1Y
MBX Biosciences, Inc. (NasdaqGS: MBX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.56B and employs 63 people.
Over the last twelve months the share price has gained 267.2%, trading between 12.94 and 72.64.
Tweenvest scores MBX Biosciences, Inc. across four factors: quality 65/100, value 88/100. Its strongest factor is value.
MBX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.56B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.41
- Dividend yield
- —
- Beta (5Y)
- 0.10
- 52-week high
- $72.64
- 52-week low
- $12.94
- Avg volume (3M)
- —
- Shares outstanding
- 48.16M
- Employees
- 63
- Next earnings
- —
About MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
- ISIN
- US55287L1017
- Founded
- 2018
- Listed since
- Sep 13, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Joincare Pharmaceutical Group Industry Co.,Ltd.SHSE: 600380 | $2.77B | CN¥10.13 | +2.32% |
| Piramal Pharma LimitedNSEI: PPLPHARMA | $2.70B | Rs196.88 | -0.55% |
| Acutaas Chemicals LimitedNSEI: ACUTAAS | $2.67B | Rs3,160.60 | -1.12% |
| Rubicon Research LimitedNSEI: RUBICON | $2.65B | Rs1,548.50 | -5.05% |
| China Resources Double-Crane Pharmaceutical Co.,Ltd.SHSE: 600062 | $2.53B | CN¥16.44 | +1.23% |
| Supernus Pharmaceuticals, Inc.NasdaqGM: SUPN | $2.48B | $42.67 | +0.68% |
| Curaleaf Holdings, Inc.TSX: CURA | $2.47B | CA$13.31 | -6.33% |
| Almirall, S.A.BME: ALM | $2.46B | €10.08 | +0.20% |
Figures last refreshed Oct 11, 2026.